Italia markets close in 1 hour 31 minutes

CRMD Sep 2024 5.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,90000,0000 (0,00%)
In data: 10:31AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,9000
Aperto0,9000
Denaro0,6500
Domanda2,6500
Prezzo d'esercizio5,00
Scadenza2024-09-20
Min-Max giorno0,9000 - 0,9000
Contratto - Min-MaxN/D
Volume1
Open Interest2,37k
  • GlobeNewswire

    CorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference

    BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract has been accepted for presentation at the IDWeek 2023 meeting being held in Boston, Massachusetts, October 11 – 15. The abstract being presented highlights data regarding in vitro activity of taurolidine agains

  • GlobeNewswire

    CorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference

    BERKELEY HEIGHTS, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will be giving a company presentation at the Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 26 – 28, 2023. Cantor Fitzgerald Global Healthcare Conference Date:Thursday,

  • GlobeNewswire

    CorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology

    BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the publication of its Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology, or CJASN. The study compared the efficacy and safety of DefenCath®, a catheter lock solution that combines